Zobrazeno 1 - 10
of 82
pro vyhledávání: '"Matthew E Layton"'
Autor:
John D. Clarke, Sabrina M. Judson, Dan‐Dan Tian, Trevor O. Kirby, Rakshit S. Tanna, Adrienn Matula‐Péntek, Miklós Horváth, Matthew E. Layton, John R. White, Nadja B. Cech, Kenneth E. Thummel, Jeannine S. McCune, Danny D. Shen, Mary F. Paine
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 10, Pp 1779-1790 (2023)
Abstract Green tea is a popular beverage worldwide. The abundant green tea catechin (−)‐epigallocatechin gallate (EGCG) is a potent in vitro inhibitor of intestinal UDP‐glucuronosyltransferase (UGT) activity (Ki ~2 μM). Co‐consuming green te
Externí odkaz:
https://doaj.org/article/3dfbcc53952945d38b75f821bdee7633
Autor:
Rakshit S. Tanna, James T. Nguyen, Deena L. Hadi, Matthew E. Layton, John R. White, Nadja B. Cech, Nicholas H. Oberlies, Allan E. Rettie, Kenneth E. Thummel, Mary F. Paine
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:1315-1325
Autor:
Rakshit S. Tanna, James T. Nguyen, Deena L. Hadi, Preston K. Manwill, Laura Flores-Bocanegra, Matthew E. Layton, John R. White, Nadja B. Cech, Nicholas H. Oberlies, Allan E. Rettie, Kenneth E. Thummel, Mary F. Paine
Publikováno v:
Pharmaceutics, Vol 14, Iss 3, p 620 (2022)
Increasing use of the botanical kratom to self-manage opioid withdrawal and pain has led to increased kratom-linked overdose deaths. Despite these serious safety concerns, rigorous fundamental pharmacokinetic knowledge of kratom in humans remains lac
Externí odkaz:
https://doaj.org/article/695db9b4d5e444cca0a9e8858c495f96
Publikováno v:
Pain Management Nursing. 23:616-624
Pain, drug cravings, and opioid withdrawal symptoms can interfere with substance use disorder or opioid tapering treatment goals.This pilot study investigated the feasibility of a protocol designed to test opioid withdrawal symptom relief relative to
Publikováno v:
Military Medicine. 186:246-252
Introduction Military operations often involve intense exposure to stressors combined with acute sleep deprivation, while military personnel also experience high prevalence of chronic sleep deficiency from insomnia and other sleep disorders. However,
Autor:
Michelle A. Schmidt, Dawn M. DePriest, Jonathan P. Wisor, Rachael A Muck, Kimberly A. Honn, Hans P. A. Van Dongen, Brieann C. Satterfield, Matthew E. Layton
Publikováno v:
Chronobiology International. 37:1457-1460
Total sleep deprivation (TSD) and time-on-task (TOT), especially in combination, increase cognitive instability and cause performance impairment. There are large inter-individual differences in TSD...
Publikováno v:
Pain Management Nursing. 21:94-99
Background Adults with persistent pain frequently report cannabis use to help manage their symptoms. The impact of cannabis use on cognition in the presence of concurrent symptoms of depression and anxiety is poorly understood. Aims Our study explore
Publikováno v:
Nature and Science of Sleep. 11:401-410
Purpose Individuals with primary insomnia frequently report cognitive impairment as a next-day consequence of disrupted sleep. Studies attempting to quantify daytime impairment objectively in individuals with insomnia have yielded mixed results, with
Autor:
Lillian Skeiky, Devon A Hansen, Matthew E. Layton, Gemma M. Paech, Hans P. A. Van Dongen, Brieann C. Satterfield, Julie A Erwin
Publikováno v:
Chronobiology international. 37(9-10)
There are large inter-individual differences in slow wave sleep, which constitute a trait or phenotype. We investigated whether the manifestation of this trait is impacted by daytime sleeping after sleep deprivation, and to what extent it is robust t
Autor:
Deena L. Hadi, Rakshit S. Tanna, Jashvant D. Unadkat, Mary F. Paine, Nadja B. Cech, Sumit Bansal, Justina C. Calamia, Matthew E. Layton, Kenneth E. Thummel, Dan-Dan Tian, Miklós Horváth, Christopher M. Arian, Bálint Molnár, Joshua J. Kellogg, Laura M. Shireman, John R. White, James Nguyen, Richard D. Boyce
Publikováno v:
Clin Pharmacol Ther
The botanical natural product goldenseal can precipitate clinical drug interactions by inhibiting cytochrome P450 (CYP) 3A and CYP2D6. Besides P-glycoprotein, effects of goldenseal on other clinically relevant transporters remain unknown. Established